Multi-Subunit SARS-CoV-2 Vaccine Design Using Evolutionarily Conserved T- and B- Cell Epitopes.
Multi-Subunit SARS-CoV-2 Vaccine Design Using Evolutionarily Conserved T- and B- Cell Epitopes.
复制标题
DOI：
10.3390/vaccines9070702
复制
发表时间：
2021-06-26
期刊：
影响因子：
7.8
通讯作者：
Ali S
中科院分区：
文献类型：
--
作者：
Akbay B;Abidi SH;Ibrahim MAA;Mukhatayev Z;Ali S
The SARS-CoV-2 pandemic has created a public health crisis worldwide. Although vaccines against the virus are efficiently being rolled out, they are proving to be ineffective against certain emerging SARS-CoV-2 variants. The high degree of sequence similarity between SARS-CoV-2 and other human coronaviruses (HCoV) presents the opportunity for designing vaccines that may offer protection against SARS-CoV-2 and its emerging variants, with cross-protection against other HCoVs. In this study, we performed bioinformatics analyses to identify T and B cell epitopes originating from spike, membrane, nucleocapsid, and envelope protein sequences found to be evolutionarily conserved among seven major HCoVs. Evolutionary conservation of these epitopes indicates that they may have critical roles in viral fitness and are, therefore, unlikely to mutate during viral replication thus making such epitopes attractive candidates for a vaccine. Our designed vaccine construct comprises of twelve T and six B cell epitopes that are conserved among HCoVs. The vaccine is predicted to be soluble in water, stable, have a relatively long half-life, and exhibit low allergenicity and toxicity. Our docking results showed that the vaccine forms stable complex with toll-like receptor 4, while the immune simulations predicted that the vaccine may elicit strong IgG, IgM, and cytotoxic T cell responses. Therefore, from multiple perspectives, our multi-subunit vaccine design shows the potential to elicit a strong immune-protective response against SARS-CoV-2 and its emerging variants while carrying minimal risk for causing adverse effects.
登录
查看更多内容
影响因子：
32.4
作者：
Ferretti AP;Kula T;Wang Y;Nguyen DMV;Weinheimer A;Dunlap GS;Xu Q;Nabilsi N;Perullo CR;Cristofaro AW;Whitton HJ;Virbasius A;Olivier KJ Jr;Buckner LR;Alistar AT;Whitman ED;Bertino SA;Chattopadhyay S;MacBeath G
通讯作者：
MacBeath G
T细胞和抗体动力学描述了介导共证疗法个体中介导长期免疫反应的SARS-COV-2肽。
影响因子：
17.1
作者：
Bilich T;Nelde A;Heitmann JS;Maringer Y;Roerden M;Bauer J;Rieth J;Wacker M;Peter A;Hörber S;Rachfalski D;Märklin M;Stevanović S;Rammensee HG;Salih HR;Walz JS
通讯作者：
Walz JS
影响因子：
--
作者：
Corman VM;Muth D;Niemeyer D;Drosten C
通讯作者：
Drosten C
影响因子：
29.7
作者：
Brubaker SW;Bonham KS;Zanoni I;Kagan JC
通讯作者：
Kagan JC
影响因子：
3.7
作者：
Gupta S;Kapoor P;Chaudhary K;Gautam A;Kumar R;Open Source Drug Discovery Consortium;Raghava GP
通讯作者：
Raghava GP